Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab with carboplatin/paclitaxel for advanced ovarian cancer
ACTRN12618000109202Phase 2Completed
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Start
- Jul 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab, tremelimumab, carboplatin and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Australia New Zealand Gynaecological Oncology Group. Primary endpoint: Pathological complete response. Started Jul 2018; status: completed.
02
Drugs
durvalumabtremelimumabcarboplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12618000109202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000109202.